You are here

Advanced Manufacturing Process for High Performance MRI Contrast Agents

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43EB018174-01A1
Agency Tracking Number: R43EB018174
Amount: $224,997.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NIBIB
Solicitation Number: PA13-234
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
ROANOKE, VA 24016-4961
United States
DUNS: 627132913
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (434) 483-4254
Business Contact
Phone: (434) 483-4254
Research Institution

DESCRIPTION (provided by applicant): Contrast-enhanced magnetic resonance imaging is widely used for non-invasive diagnosis of a variety of diseases. However due to the intrinsic properties of existing gadolinium-chelate contrast agents, there exist clinical needs of improved MRI contrast agents that render extended circulatory half-life enabling blood pool imaging with favorable biodistribution and enabling tissue-specific imaging; reduce Gd associated long term safety concerns; have greater relaxivity andgenerate positive contrast enhancement. Luna is developing metallofullerene-based T1 agents for both blood pool imaging and targeted imaging of cancer and atherosclerotic plaque. We have conducted extensive animal studies demonstrating substantially improved imaging sensitivity at lower does, and no acute toxicity was found. It is a very promising new T1 contrast agent platform technology. However, to be cost competitive and capable of producing clinically relevant quantities, it is necessary to improve th

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government